Nichakawade et al. developed a TRBC1-targeted ADC, which demonstrated potent anti-tumor properties using two different payloads (MMAE and tesirine) in mouse models with TRBC1+ T-cell cancer (Jurkat) cells [103]. The gene discussed is TRBC1; the disease is neoplasm.